CO6251371A2 - Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino - Google Patents
Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murinoInfo
- Publication number
- CO6251371A2 CO6251371A2 CO10014090A CO10014090A CO6251371A2 CO 6251371 A2 CO6251371 A2 CO 6251371A2 CO 10014090 A CO10014090 A CO 10014090A CO 10014090 A CO10014090 A CO 10014090A CO 6251371 A2 CO6251371 A2 CO 6251371A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- chain
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- 102000048426 human CD37 Human genes 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpos anti-CD37 quiméricos yhumanizados y composiciones farmacéuticas que loscontienen son útiles para el tratamiento de malignidades delas células B y enfermedades autoinmunes e inflamatoriasque implican células B en su patología.1.- Una molécula de anticuerpo que se une a CD37humano y que se obtiene a partir dea) un anticuerpo monoclonal murino que está definido pori) una cadena pesada variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO: 2; yii) una cadena ligera variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO:4, o apartir deb) un anticuerpo no humano que reconoce el mismoepítopo de CD37 humano que el anticuerpo definido en a)o que reconoce un epítopo que está cerca de o sesuperpone con dicho epítopo;en el que dicha molécula de anticuerpo es un anticuerpoquimérico o humanizado.2.- Una molécula de anticuerpo de la reivindicación 1que es un anticuerpo quimérico definido pori) una cadena pesada variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO: 2;ii) una cadena ligera variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO:4,iii) cadenas pesadas y ligeras constantes que son deorigen humano.3.- Un anticuerpo de la reivindicación 2, en el quei) la cadena pesada constante es una cadena lgG1, yii) la cadena ligera constante es una cadena kappa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114128 | 2007-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6251371A2 true CO6251371A2 (es) | 2011-02-21 |
Family
ID=38925567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10014090A CO6251371A2 (es) | 2007-08-09 | 2010-02-09 | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US20100189722A1 (es) |
| EP (3) | EP2241577A1 (es) |
| JP (3) | JP5325216B2 (es) |
| KR (1) | KR101593403B1 (es) |
| CN (4) | CN101815725A (es) |
| AR (2) | AR071242A1 (es) |
| AU (1) | AU2008285590B2 (es) |
| BR (2) | BRPI0823331A2 (es) |
| CA (1) | CA2693464C (es) |
| CL (3) | CL2008002349A1 (es) |
| CO (1) | CO6251371A2 (es) |
| CY (1) | CY1117101T1 (es) |
| DK (1) | DK2178915T3 (es) |
| EA (2) | EA201200994A1 (es) |
| EC (2) | ECSP109946A (es) |
| ES (1) | ES2555202T3 (es) |
| HK (1) | HK1220708A1 (es) |
| HR (1) | HRP20160009T1 (es) |
| HU (1) | HUE026221T2 (es) |
| IL (1) | IL202645A (es) |
| MA (1) | MA32665B1 (es) |
| ME (1) | ME02300B (es) |
| MY (1) | MY157555A (es) |
| NZ (2) | NZ600022A (es) |
| PE (3) | PE20140196A1 (es) |
| PH (1) | PH12014501812A1 (es) |
| PL (1) | PL2178915T3 (es) |
| PT (1) | PT2178915E (es) |
| RS (1) | RS54359B1 (es) |
| SG (1) | SG190657A1 (es) |
| SI (1) | SI2178915T1 (es) |
| TN (1) | TN2010000068A1 (es) |
| TW (2) | TW201512220A (es) |
| UA (2) | UA105445C2 (es) |
| UY (1) | UY31275A1 (es) |
| WO (1) | WO2009019312A2 (es) |
| ZA (1) | ZA200908758B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
| CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CA2700673A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| CN102770453B (zh) * | 2009-12-23 | 2014-10-08 | 合成免疫股份有限公司 | 抗flt3抗体及其使用方法 |
| NO331080B1 (no) | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| CN106046159B (zh) * | 2010-03-12 | 2020-06-16 | 德彪发姆国际有限公司 | Cd37结合分子及其免疫缀合物 |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20120107317A1 (en) * | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| CN103596590A (zh) * | 2011-04-01 | 2014-02-19 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
| CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| EP2790740A1 (en) * | 2011-12-13 | 2014-10-22 | Nordic Nanovector AS | Chimeric therapeutic anti - cd37 antibodie hh1 |
| WO2013149171A2 (en) * | 2012-03-30 | 2013-10-03 | Immunogen, Inc. | Methods for increasing efficacy of cd37-based therapy |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| WO2013171287A1 (en) * | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体の更なる薬剤との併用 |
| US9539259B2 (en) * | 2012-05-23 | 2017-01-10 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| WO2014151438A1 (en) * | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
| JP2016527200A (ja) * | 2013-06-14 | 2016-09-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とクロラムブシルの併用 |
| SG11201600587VA (en) | 2013-08-01 | 2016-02-26 | Agensys Inc | Antibody drug conjugates (adc) that bind to cd37 proteins |
| US9291244B2 (en) | 2014-01-17 | 2016-03-22 | Ford Global Technologies, Llc | Nine speed automatic transmission |
| EP2966085A1 (en) | 2014-07-11 | 2016-01-13 | Boehringer Ingelheim International GmbH | Antibody IgG1 with a modified heavy chain constant region |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| MA44391A (fr) | 2015-06-08 | 2019-01-23 | Debiopharm Int Sa | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 |
| PT3124976T (pt) * | 2015-07-28 | 2018-11-20 | Hoffmann La Roche | Ensaio melhorado de endotoxinas bacterianas para a determinação de endotoxinas |
| EA201890347A1 (ru) | 2015-08-28 | 2018-09-28 | Дебиофарм Интернэшнл, С.А. | Антитела и исследования для обнаружения cd37 |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| MX2019006340A (es) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN110461363B (zh) | 2017-03-16 | 2024-04-02 | 综合医院公司 | 靶向cd37的嵌合抗原受体 |
| UA127586C2 (uk) | 2017-03-31 | 2023-10-25 | Ґенмаб Холдінґ Б.В. | Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування |
| EP3644722A1 (en) | 2017-06-27 | 2020-05-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized asgr1 locus |
| JP7513530B2 (ja) | 2018-06-22 | 2024-07-09 | ジェンマブ ホールディング ビー．ブイ． | 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法 |
| CN112292140A (zh) * | 2018-06-22 | 2021-01-29 | 综合医院公司 | 靶向cd37和cd19的嵌合抗原受体 |
| JPWO2020004337A1 (ja) * | 2018-06-27 | 2021-08-02 | 国立大学法人東海国立大学機構 | Ｃｄ３７特異的キメラ抗原レセプター |
| CA3115163A1 (en) | 2018-10-04 | 2020-04-09 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| CN114650867A (zh) * | 2019-08-30 | 2022-06-21 | 齐鲁普吉湾生物治疗公司 | 抗cd20抗体、抗cd37抗体及它们的混合物 |
| WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| IL312237A (en) * | 2021-10-18 | 2024-06-01 | Daiichi Sankyo Co Ltd | Anti-CD37 antibody-drug conjugate |
| WO2024118480A1 (en) * | 2022-11-28 | 2024-06-06 | Epiphany Biosciences | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| DE68908175T2 (de) | 1988-05-27 | 1994-03-03 | Centocor Inc | Gefriergetrocknete formulierung für antikörperprodukte. |
| ES2146572T3 (es) * | 1988-09-06 | 2000-08-16 | Xoma Technology Ltd | Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano. |
| DK0393438T3 (da) | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE233813T1 (de) | 1991-08-14 | 2003-03-15 | Genentech Inc | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK0703925T3 (da) | 1993-06-03 | 1999-12-06 | Therapeutic Antibodies Inc | Fremstilling af antistoffragmenter |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| ES2300113T3 (es) | 1996-08-02 | 2008-06-01 | Bristol-Myers Squibb Company | Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo. |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| HUP0100813A3 (en) | 1998-02-25 | 2003-08-28 | Lexigen Pharmaceuticals Corp L | Enhancing the circulating half-life of antibody-based fusion proteins |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
| ES2274823T3 (es) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica. |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| JP4498746B2 (ja) * | 2002-02-14 | 2010-07-07 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法 |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| US7425619B2 (en) | 2002-08-14 | 2008-09-16 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| EP1534336A4 (en) | 2002-08-15 | 2005-12-14 | Human Genome Sciences Inc | ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS |
| EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
| ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| MX342007B (es) | 2003-05-14 | 2016-09-09 | Immunogen Inc | Composicion de farmaco conjugado. |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| AU2006299429B2 (en) * | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| KR101574920B1 (ko) | 2005-10-12 | 2015-12-04 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| EP2318048B1 (en) | 2008-07-21 | 2019-05-29 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| WO2010057047A1 (en) | 2008-11-13 | 2010-05-20 | Trubion Pharmaceutics, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| US20120189618A1 (en) | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| WO2013171287A1 (en) * | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体の更なる薬剤との併用 |
| JP2016527200A (ja) | 2013-06-14 | 2016-09-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とクロラムブシルの併用 |
-
2008
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 RS RS20150817A patent/RS54359B1/en unknown
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko active IP Right Grant
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en active Application Filing
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
-
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
-
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
-
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
-
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
-
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
-
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812A1/en unknown
-
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
-
2016
- 2016-01-05 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
-
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
-
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
-
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251371A2 (es) | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino | |
| PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
| CA2808482C (en) | Methods for the generation of multispecific and multivalent antibodies | |
| AR052889A1 (es) | Anticuerpos contra interleuquina-1 beta | |
| UY29573A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| AR052065A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
| UY30260A1 (es) | Anticuerpos dirigidos contra upar y usos de los mismos | |
| EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
| PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
| AR062213A1 (es) | Anticuerpos dirigidos contra (alfa v beta 6) y usos de los mismos | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| WO2013144566A3 (en) | Animals expressing human lambda immunoglobulin light chain variable domain | |
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| MX2009008230A (es) | Epitopes de celulas t reguladoras, composiciones y usos para los mismos. | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |